In recent years the research and development is focused much on innovative biologic and spurring the introduction and access to biosimilars. The FDA has issued several drafts and final guidance to assist biosimilar sponsors in generating data to support biosimilar applications. The FDA guidance and regulations provide insights regarding evaluation of biosimilars. The FDA is working to provide additional guidance on how biosimilar products could be designated to reference products. This session brings out the current, on-going researches and new regulations with respect to biologic and biosimilars.
Related: Drug Delivery Conferences | Pharmaceutical Sciences Conferences | Pharmaceutical Conference | Drug Discovery Conferences | Pharmacy Conferences | Pharmacology Conferences
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
